Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Elite Pharmaceuticals Inc. (ELTP) had Revenue of $40.75M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$40.75M
Net Income	$18.46M
Cost of Goods Sold	$19.98M
Gross Profit	$20.77M
Operating Expenses	$30.56M
Operating Income	$10.19M
Non-Operating Income/Expense	$10.67M
Pre-Tax Income	$20.85M
Normalized Pre-Tax Income	$20.85M
Income after Taxes	$18.46M
Income from Continuous Operations	$18.46M
Consolidated Net Income/Loss	$18.46M
Normalized Income after Taxes	$18.46M
EBIT	$10.19M
EBITDA	$10.68M
Weighted-Average Shares Outstanding (Basic)	1.07B
Weighted-Average Shares Outstanding (Diluted)	1.14B
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.02
Balance Sheet Financials
Current Assets	$112.11M
Property, Plant, and Equipment	$10.18M
Long-Term Assets	$26.18M
Total Assets	$138.29M
Current Liabilities	$17.39M
Long-Term Debt	$3.66M
Long-Term Liabilities	$22.02M
Total Liabilities	$39.41M
Common Equity	$98.88M
Tangible Shareholders Equity	$94.09M
Shareholders Equity	$98.88M
Common Shares Outstanding	1.08B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$23.75M
Cash Flow from Investing Activities	$-0.93M
Cash Flow from Financial Activities	$-4.32M
Beginning Cash	$11.77M
End Cash	$30.27M
Increase/Decrease in Cash	$18.50M
Stock-Based Compensation	$0.18M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.45
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.04
Debt to Equity Ratio	0.04
Gross Margin	50.98%
Operating Margin	25.00%
EBIT Margin	25.00%
EBITDA Margin	--
Pre-Tax Profit Margin	51.18%
Profit Margin	45.31%
Free Cash Flow	$22.82M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.29
Inventory Turnover	0.94
Receiveable Turnover	0.68
Days Sales in Receivables	131.89
Return on Equity	18.67%
Return on Tangible Equity	19.62%
Return on Assets	13.35%
Return on Investments	18.00%
Book Value Per Share	$0.09
Free Cash Flow per Share	$0.02
Operating Cash Flow per Share	$0.02

Data from Zacks Investment Research, Inc.